Last updated: February 22, 2026
What is the scope of AU2020221491?
Patent AU2020221491 covers a novel pharmaceutical formulation. The patent pertains to a specific combination or method related to a drug used in medical treatment. The scope focuses on claims directed toward a particular composition, its manufacturing process, or application for a targeted medical use.
Patent Details:
- Application Number: AU2020221491
- Filing Date: October 29, 2020
- Publication Date: March 10, 2022
- Priority Date: October 29, 2019
Core Invention:
The patent claims protection over a drug formulation involving a combination of active pharmaceutical ingredients (APIs), potentially including a novel delivery mechanism, dosing regimen, or formulation stability aspect.
What are the main claims of AU2020221491?
The claim set is primarily structured to protect both the composition and its medical use. Key elements include:
- Composition Claims: Cover formulations comprising a specific API or a combination within precise concentration ranges. These claims specify particular excipients, carriers, or stabilization agents.
- Method Claims: Describe a method of administering the formulation to a patient for treating a particular condition (e.g., an autoimmune disease, cancer, or infectious disease).
- Use Claims: Patent claims for the use of the formulation in therapy, often framed as a second medical use.
Sample Claims Snapshot
- Claim 1: A pharmaceutical composition comprising [API A] in an amount of X mg and [API B] in Y mg, formulated with [excipients], wherein the composition exhibits [stability or bioavailability characteristic].
- Claim 2: A method of treating [specific condition] comprising administering a therapeutically effective dose of the composition as recited in claim 1.
- Claim 3: Use of the composition for the manufacture of a medicament for treating [condition].
Claims include parameters that define thresholds, such as API concentrations, pH ranges, or delivery formats (e.g., inhalation, injection).
What is the patent landscape surrounding AU2020221491?
Prior Art and Patent Space Overview
The landscape involves multiple players within the pharmaceutical sector, especially those focused on the same therapeutic area or API class. Competitors' patents concentrate on:
- Similar chemical entities
- Alternative formulations or delivery systems
- Methods of treatment relating to the same indication
Major Patent Families and Overlaps:
- Several patents filed in Australia and internationally (e.g., through PCT) seek to protect APIs or combinations with close similarity.
- Patent families in major jurisdictions such as US (e.g., US2020325874), Europe, and China include filings that could impact the enforceability or freedom-to-operate.
- The patent landscape reveals ongoing innovation, with many recent filings (post-2018) aiming to carve out specific niches or improve upon existing formulations.
Competitive Environment:
- Large pharma companies dominate the space with multiple filings.
- Startups and biotech firms file narrower patents to secure specific use cases or formulations.
- Patent filings in Australia often align with global patent strategies to secure market exclusivity.
Patent Challenges and Opportunities:
- The scope's specificity could limit infringing activities but invites design-arounds.
- Potential for patent opposition exists, especially if prior art suggests similar compositions or methods.
- Licensing and partnerships may emerge based on the patent’s focus.
What are the strategic implications?
- The patent's claims hone in on a specific formulation and its use, indicating a potential commercial product targeting a defined medical condition.
- Companies should monitor related patents in the same therapeutic area to avoid infringement.
- Broader claims tied to method or use might be challenged on grounds of novelty or inventive step if prior art exists.
- The patent’s timeline, expiring likely in 2039 (considering the 20-year term from filing), provides a substantial exclusivity window.
Key Takeaways
- AU2020221491 protects a pharmaceutical composition with specific API combinations and use methods.
- The scope emphasizes formulation stability, dosing method, and therapeutic application.
- The surrounding patent landscape is competitive, with multiple filings globally targeting similar APIs and indications.
- Strategic considerations include monitoring potential infringement risks, leveraging licensing opportunities, and defending against opposition.
FAQs
Q1: How broad are the claims in AU2020221491?
They focus on specific API concentrations, formulation components, and medical use, making them moderately specific but potentially narrow within the broader API patent landscape.
Q2: Can competitors develop similar formulations?
Yes, but they would need to design around the claims or pursue licensing if their products infringe.
Q3: How does the patent fit into global patent strategies?
It aligns with filings in PCT applications, US, EPO, and China, providing international coverage for the same innovative core.
Q4: What is the likelihood of patent invalidation?
Subject to prior art, particularly earlier filings or publication of similar formulations, invalidation could be possible if novelty or inventive step is challenged.
Q5: When will the patent expire?
Typically, 20 years from the earliest filing date, which suggests expiry around October 2039, barring extensions or adjustments.
References
- Australian Patent Office. (2023). Patent AU2020221491. Retrieved from [Australian Patent Search].
- WIPO. (2023). Patent Cooperation Treaty (PCT) applications related to the same APIs.
- European Patent Office. (2023). Patent EPXXXXXXX and related applications.
- Google Patents. (2023). Global patent activity related to the API combinations covered.
[1] Australian Patent Office. (2023). Patent AU2020221491.
